Currently out of the existing stock ratings of Thomas Wei, 3 are a SELL (9.09%), 3 are a HOLD (9.09%), 27 are a BUY (81.82%).

Thomas Wei

Work Performance Price Targets & Ratings Chart

Analyst Thomas Wei works with a stock forecast success ratio of 83.33% fulfilled within 586.5 days on average. Previously, Thomas Wei worked at JEFFERIES.

Thomas Wei’s has documented 68 price targets and ratings displayed on 10 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on STML, Stemline Therapeutics at 22-Apr-2015.

Wall Street Analyst Thomas Wei

Analyst best performing recommendations are on ACAD (ACADIA PHARMACEUTICALS).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 5/6/2013. The price target of $18 was fulfilled within 35 days with a profit of $5.82 (47.78%) receiving and performance score of 13.65.

Average potential price target upside

AMRN Amarin PLC BIIB Biogen DVAX Dynavax Technologies INCY yte VVUS VIVUS ACAD ACADIA Pharmaceuticals NBIX Neurocrine Biosciences STML Stemline Therapeutics ARNA Arena Pharmaceuticals ARWR Arrowhead Pharmaceuticals

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

5 months 3 days ago

1/3 (33.33%)

$-0.04 (-0.99%)

300

Hold

1

$-0.07 (-6.54%)

5

5 months 29 days ago

4/21 (19.05%)

$0.29 (40.85%)

32

Sell

1

$-0.07 (-6.54%)

3.5

9 months 4 days ago

8/11 (72.73%)

$-0.08 (-7.41%)

55

Hold

1.25

$0.18 (16.82%)

2

9 months 4 days ago

2/5 (40%)

$0.17 (15.74%)

215

Buy

10

1 years 10 months 1 days ago

13/47 (27.66%)

$6.81 (213.48%)

194

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Thomas Wei?

On 2009

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?